MedTrace Logo

TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

NCT03698825 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-12-09

No results posted yet for this study

Summary

This is an open-label, single arm study evaluating the safety and tolerability of TEW-7197 in combination with paclitaxel in metastatic gastric cancer patients.

Conditions

  • Metastatic Gastric Cancer

Interventions

DRUG

TEW-7197

TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study

Sponsors & Collaborators

  • MedPacto, Inc.

    lead INDUSTRY

Principal Investigators

  • Sunjin Hwang, MD · MedPacto, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-15
Primary Completion
2022-01-03
Completion
2022-12-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698825 on ClinicalTrials.gov